Darifenacin
Darifenacin Brand names, Darifenacin Analogs
Darifenacin Brand Names Mixture
- Cystosol W 3% Hexitols (Mannitol + Sorbitol)
- Sorbitol Mannitol Irrigation (Mannitol + Sorbitol)
Darifenacin Chemical_Formula
C28H30N2O2
Darifenacin RX_link
http://www.rxlist.com/cgi/generic3/enablex.htm
Darifenacin fda sheet
Darifenacin msds (material safety sheet)
Darifenacin Synthesis Reference
No information avaliable
Darifenacin Molecular Weight
426.55 g/mol
Darifenacin Melting Point
No information avaliable
Darifenacin H2O Solubility
No information avaliable
Darifenacin State
Solid
Darifenacin LogP
4.832
Darifenacin Dosage Forms
Extended-release tablets (containing 7.5 mg or 15 mg darifenacin as hydrobromide salt)
Darifenacin Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Darifenacin Pharmacology
Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
Darifenacin Absorption
The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Darifenacin side effects and Toxicity
Overdosage can potentially result in severe central anticholinergic effects.
Darifenacin Patient Information
Darifenacin Organisms Affected
Humans and other mammals
